Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 1
2007 1
2008 1
2009 9
2010 8
2011 2
2012 8
2013 2
2014 8
2015 3
2016 7
2017 5
2019 3
2020 3
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J. Sharma SV, et al. Among authors: settleman j. Cell. 2010 Apr 2;141(1):69-80. doi: 10.1016/j.cell.2010.02.027. Cell. 2010. PMID: 20371346 Free PMC article.
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Lynch TJ, et al. Among authors: settleman j. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29. N Engl J Med. 2004. PMID: 15118073 Free article.
Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure.
Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, Kim HJ, Wongchenko M, Yan Y, Haley B, Cuellar T, Webster J, Alag N, Hegde G, Jackson E, Nance TL, Giresi PG, Chen KB, Liu J, Jhunjhunwala S, Settleman J, Stephan JP, Arnott D, Classon M. Guler GD, et al. Among authors: settleman j. Cancer Cell. 2017 Aug 14;32(2):221-237.e13. doi: 10.1016/j.ccell.2017.07.002. Epub 2017 Aug 3. Cancer Cell. 2017. PMID: 28781121 Free article.
TORquing metabolic reprogramming in cancer cells.
Pusapati R, Settleman J. Pusapati R, et al. Among authors: settleman j. Cell Cycle. 2016 Sep 16;15(18):2387-8. doi: 10.1080/15384101.2016.1204850. Epub 2016 Jun 30. Cell Cycle. 2016. PMID: 27362787 Free PMC article. No abstract available.
Dissecting cancer heterogeneity.
Dornan D, Settleman J. Dornan D, et al. Among authors: settleman j. Nat Biotechnol. 2011 Dec 8;29(12):1095-6. doi: 10.1038/nbt.2063. Nat Biotechnol. 2011. PMID: 22158362 No abstract available.
Thinking Differently about Cancer Treatment Regimens.
Settleman J, Neto JMF, Bernards R. Settleman J, et al. Cancer Discov. 2021 May;11(5):1016-1023. doi: 10.1158/2159-8290.CD-20-1187. Epub 2021 Mar 1. Cancer Discov. 2021. PMID: 33648929
Oncogenic K-ras "addiction" and synthetic lethality.
Singh A, Settleman J. Singh A, et al. Among authors: settleman j. Cell Cycle. 2009 Sep 1;8(17):2676-7. doi: 10.4161/cc.8.17.9336. Epub 2009 Sep 23. Cell Cycle. 2009. PMID: 19690457 Free PMC article.
Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C, Settleman J. Montagut C, et al. Among authors: settleman j. Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12. Cancer Lett. 2009. PMID: 19217204 Review.
65 results